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Abstract
Objective: While prior Epstein–Barr virus (EBV) infection has been consis-
tently associated with subsequent risk of developing multiple sclerosis (MS), the
association with other common herpesviruses has been more controversial. Our
objectives were to determine whether remote infection with EBV and other
common herpesviruses affect the susceptibility to pediatric MS and if there are
interactions between genetic and demographic factors and viral infections.
Methods: Cases with pediatric-onset MS or clinically isolated syndrome within
4 years of disease onset, and controls were recruited from 16 American pedi-
atric MS centers. Logistic regression models adjusted for potential confounders
assessed the association between case status and serological evidence for past
infection with EBV, cytomegalovirus (CMV), Herpes Simplex viruses-1 (HSV-
1) and -2. We determined the heterogeneity of the effect of viral infection on
the risk of having MS according to race, ethnicity and HLA-DRB1:1501 status.
Results: A total of 356 pediatric cases and 493 controls were recruited. In mul-
tivariable models, EBV-viral capsid antigen (VCA) seropositivity was associated
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conducted the statistical analysis.
with increased odds of having MS by 7.4 times (95% CI: 4.5–12.0, P < 0.001).
Seropositivity for HSV-1 was also associated with increased odds of having MS
(OR 1.54, 95% CI: 1.06–2.25, P = 0.025) but this increase was seen only in
Whites (OR = 2.18, 95% CI 1.35–3.52, P < 0.001) and those negative for HLA-
DRB1*1501 (OR = 1.89, 95% CI 1.17–3.03, P = 0.009). The effect of remote
EBV infection on the risk of pediatric MS depended on race and HLA-
DRB1*15:01 status. Interpretation: EBV seropositivity is strongly associated
with pediatric MS, as is HSV-1 seropositivity in subjects negative for HLA-
DRB1*15:01. Our report of interactions between select viral exposures, and age,
race and DRB1 status suggests a complex effect of environmental and genetic
risk factors on MS development.
Introduction
Genetic and environmental risk factors and their interac-
tions determine an individual’s risk of developing multi-
ple sclerosis (MS).1 Approximately 200 common genetic
variants that alter the risk of MS onset have been
described in white adults2 and HLA-DRB1*15:01 has the
largest effect. Environmental risk factors consistently asso-
ciated with MS susceptibility include prior infection with
EBV, exposure to cigarette smoking, vitamin D deficiency
and obesity.1 Exposures to commonly encountered viruses
have also been linked to MS susceptibility. The most
well-studied ones include Epstein–Barr virus (EBV), cyto-
megalovirus (CMV) and Herpes Simplex virus (HSV).
While prior infection with EBV is reported in most
patients with adult or pediatric-onset MS,1 a few studies
have suggested that remote CMV exposure might decrease
the risk of having MS.3,4
Although interactions between genetic and environ-
mental factors have been suspected to modulate MS risk,
only a few have been reported5–8 in part due to limited
study sample sizes and extent of available data. Patients
with pediatric-onset MS may have a higher burden of
genetic susceptibility variants and/or a greater dose of
environmental exposures, resulting in much earlier disease
onset and as such, finding gene-environment interactions
may be easier in this age group.
We have reported the association between prior expo-
sure to several herpesviruses and MS susceptibility in
pediatric MS4 and suggested evidence for an interaction
between HLA-DRB1*15:01 status and HSV-1. Although
several other studies investigated the association of prior
viral infections and pediatric MS risk,9–13 very few studies
examining the risk of MS in relation to previous viral
exposures and the possible interactions with age, race and
ethnicity have been conducted.14 Using a large case–con-
trol study, we aimed to assess the heterogeneity of associ-
ation between remote infections with common
herpesviruses and the risk of pediatric MS in children
with a diverse racial and ethnic background.
Methods
Participating sites
This is a case–control study of risk factors in pediatric MS
(R01NS071463, PI Waubant). The participating centers
include University of California San Francisco, State
University of New York at Buffalo, Massachusetts General
Hospital for Children, Mayo Clinic Rochester, Stony
Brook University Medical Center, Texas Children’s Hospi-
tal Baylor, Loma Linda University, Children’s Hospital of
Philadelphia, Ann & Robert H. Lurie Children’s Hospital
of Chicago, Children’s National Medical Center, Chil-
dren’s Hospital of Colorado, University of Texas South-
western/Children’s Medical Center Dallas, Boston
Children’s Hospital, University of Alabama, Cleveland
Clinic and Washington University School of Medicine in
St. Louis. Parents completed a comprehensive environ-
mental questionnaire and data including medical history,
demographics and environmental exposures (such as par-
ental smoking) were entered into a central database. Insti-
tutional review boards at all participating centers reviewed
and approved the study. Assent and consent forms were
signed by the participants and one of the parents/guar-
dians before enrollment in the study. Participants were
recruited between November 2011 and September 2015.
Study participants
Patients with relapsing MS or clinically isolated syndrome
(CIS) with high risk for MS whose initial attack occurred
before 18 years of age, whose disease duration was less
than 4 years and who had at least two silent MRI lesions
were recruited to the study. Case status was confirmed by
a review panel of at least two pediatric MS experts. Con-
trol subjects included pediatric patients seen at general
and specialty pediatric clinics at the same institutions
during the same period. They were less than 22 years of
age, did not have autoimmune disorders except asthma
or eczema or severe health conditions and were never
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treated with immunosuppressive medications. Their par-
ents did not have MS. Of note, none of the cases or con-
trols in this study had participated in the research
previously published by this group.4
Race and ethnicity were self-reported, based on NIH
categories. We categorized the racial subgroups as whites,
African-Americans and others. Ethnicity was characterized
as Hispanic or non-Hispanic. Socio-economic status
(SES) was defined as the highest level of education
attained by the participant’s mother. Participants
answered an environmental questionnaire and provided
blood for serum and DNA.
Viral studies
Batched EBV-viral capsid antigen (VCA), CMV, HSV-1,
and HSV-2 assays (serum IgG) were tested at the Okla-
homa Medical Research Foundation by commercially
available, standardized enzyme-linked immunosorbent
assay (ELISA) (Wampole Laboratories, Princeton, NJ) as
described previously.15,16 Quality control requirements
included calibration and having positive and negative
controls that met predefined measures. We did not ana-
lyze Epstein-Barr nuclear antigen 1 (EBNA-1) seropositiv-
ity as the manufacturing source of EBNA-1 antigen
changed during the study resulting in inconsistent results.
HLA-DRB1*15:01 and 15:03 genotyping
DNA samples of cases and control subjects were tested by
single-nucleotide polymorphisms (SNPs) for the presence
of HLA-DRB1*15:01/15:03 and copy number. We used a
validated TaqMan polymerase chain reaction (PCR), as
previously described.4
Genetic ancestry inference
In a subset of cases and controls, genetic ancestry was
determined. Whole-genome single-nucleotide polymor-
phism (SNP) analysis was performed on Illumina
OmniExpress BeadChip or Illumina Infinium Human
OmniExpress Exome..17 Standard quality control (QC)
was performed. We used SNPWEIGHTS for ancestry
inference (https://www.hsph.harvard.edu/alkes-price/sof
tware/). The details are described previously.18 Briefly,
whole-genome data of the study participants were strand
aligned and merged and following QCs were performed
before inferencing genetic ancestry: SNPs with more than
10% missing or with MAF <0.01 were excluded and
individuals with less than 90% genotyping rate were
removed. These analyses were performed in PLINK v.1.9.
Then, SNPWEIGHTS was run on the merged/quality-con-
trolled data using the weights for four major ancestral
populations (European, West African, East Asian and
Native American). More than 200,000 SNPs were used for
inference. The output included three predicted principal
components and the inferred percentage ancestry.
Statistical analysis
All analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC). Descriptive statistics for participants’
demographic and clinical data were presented as percent-
age (%), using mean  standard deviation (SD) or med-
ian (range). Significant differences between cases and
controls were tested using Chi-square tests of no associa-
tion for categorical variables and Kruskal–Wallis tests for
continuous variables.
Multivariable logistic regression adjusted for age, sex,
race, ethnicity, and SES was used to test for an association
between viral serostatus and pediatric MS. Because our
research questions focused on seroconversion, EBV-VCA,
CMV, HSV-1, and HSV-2 serostatus were treated as bin-
ary variables (seropositive or seronegative). In a subanaly-
sis involving the subset of participants who underwent
genotyping for ancestry markers, we substituted the race
variable with the genetic ancestry data. P-values smaller
than 0.05 were considered statistically significant.
In separate models, we explored the multiplicative
interaction between age, race, ethnicity and DRB1 status
(HLA-DRB1*15:01/15:03 positive or negative) and the
viral serostatus, as well as the interaction between differ-
ent viral infections (such as interaction between seroposi-
tivity of EBV and CMV, EBV and HSV, and HSV and
CMV). If the P-value of the interaction term was less
than <0.15; we stratified the analysis based on that vari-
able. Age analyses used mean age to stratify the cohort.
Results
Characteristics of cases and controls
We recruited 356 pediatric MS or CIS cases with short
mean disease duration (<1 year) and 493 control subjects
who provided blood samples at the time of enrollment.
Demographics, frequency of seropositivity for EBV-VCA,
CMV, HSV-1, and -2 and HLA-DRB1 status of cases and
controls are presented in Table 1. Cases were older and the
proportion of females among cases was higher than con-
trols.
Viral seropositivity and the risk of pediatric
MS
A higher proportion of cases than controls had evidence
of prior infection with HSV-1, HSV-2 and EBV (Table 1).
1224 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Viral Infections and Risk of Pediatric MS B. Nourbakhsh et al.
In multivariable logistic regression models adjusted for
sex, age, race, ethnicity and SES, seropositivity for EBV-
VCA was associated with increased odds of having MS by
more than sevenfold (OR: 7.36, 95% CI: 4.50–12.04, P-
value <0.001). Serological evidence of prior infection with
HSV-1 was also associated with modestly increased odds
of developing MS (OR: 1.54, 95% CI: 1.06–2.25, P-
value = 0.025), while for the association with HSV-2 was
only borderline significant (OR: 1.54, 95% CI: 1.00–2.38,
P-value = 0.053). There was no association between CMV
serostatus and having pediatric MS (OR: 1.29, 95% CI:
0.92–1.80, P-value = 0.14) (Table 2). Additional adjust-
ment for HLA-DRB1 status in the models did not sub-
stantially change the results (data not shown). No
significant interaction was found between seropositivity of
EBV and CMV, EBV and HSV, or HSV and CMV (data
not shown).
Race and ethnicity
There was a statistically significant multiplicative interac-
tion between race and HSV-1, HSV-2 and EBV-VCA
serostatus on the risk of MS (P-value for the interaction
term: 0.006, 0.013 and 0.005, respectively) (Table 3).
HSV-1 and -2 seropositivity were associated with
increased risk of MS only in whites (Table 4). The effect
of EBV-VCA seropositivity was stronger in whites, as
opposed to African-Americans or others (OR = 10.64,
95% CI: 5.77–19.62, P-value <0.001 in whites; OR = 6.75,
95% CI = 1.42–31.91, P-value = 0.016 in African-Ameri-
cans; OR = 1.96, 95% CI = 0.52–7.37, P-value = 0.32 in
others) (Table 4).
The P-value for the interaction between Hispanic eth-
nicity and viral serostatus was >0.15 and so this was not
explored further (Table 3).
Age
There was a significant interaction between EBV-VCA
serostatus and age in changing the odds of having MS (P-
value of the interaction terms <0.001) (Table 3). We then
analyzed the effect of viral status for this marker in chil-
dren younger than 15 years of age (the mean age of par-
ticipants in the study) versus those who were 15 years of
age and older. Seropositivity for EBV-VCA was more




N = 356 P-value
Average
enrollment age (SD)
14.3 (3.8) 15.2 (3.2) <0.0011
Average disease
duration in days (SD)
– 347 (319)
Sex <0.0012
Male 237 (48.1%) 127 (35.7%)
Female 256 (51.9%) 229 (64.3%)
Race 0.8482
White 321 (69.5%) 224 (67.7%)
Black 80 (17.3%) 62 (18.7%)
Other 61 (13.2%) 45 (13.6%)
Ethnicity <0.0012
Hispanic or latino 84 (18.0%) 108 (31.8%)
Not hispanic or latino 383 (82.0%) 232 (68.2%)
Mother’s education <0.0012
None 26 (6.0%) 35 (11.3%)
High school or Associate’s 203 (47.0%) 176 (56.6%)
Bachelor’s or Graduate 203 (47.0%) 100 (32.2%)
Positive for HSV-1 97 (20.0%) 93 (26.4%) 0.0292
Positive for HSV-2 61 (12.6%) 65 (18.7%) 0.0152
Positive for CMV 156 (32.0%) 134 (38.0%) 0.0712
Positive for EBV-VCA 284 (58.2%) 325 (91.6%) <0.0012
Positive for
DRB1*15:01 or 15:03
109 (22.1%) 141 (40.2%) <0.0012
1Kruskal–Wallis test.
2Chi-squared test of no association.
Table 2. Multivariable association between serostatus and the odds
of pediatric MS.
Effect for positive vs. negative* Odds ratio 95% CI P-value
HSV-1 1.54 1.06–2.25 0.025
HSV-2 1.54 1.00–2.38 0.053
CMV 1.29 0.92–1.80 0.142
EBV-VCA 7.36 4.50–12.04 <0.001
*Adjusted for age, sex, race, ethnicity, and mother’s highest level of
education as a measure of socio-economic status. Further adjusting
for DRB1 status did not change the results significantly.
Table 3. Multiplicative interaction test between serostatus and race,


















ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 1225
B. Nourbakhsh et al. Viral Infections and Risk of Pediatric MS
strongly associated with MS in those who were 15 years
of age or older (Table 4).
DRB1 interaction
Using multiplicative interaction terms (between carrying
HLA-DRB1 allele and viral serostatus) and considering
the P-value of <0.15 for further exploration in stratified
analysis, the presence of HLA-DRB1 modified the effect
of seropositivity for HSV-1 on the risk of pediatric MS
(Table 3). HSV-1 positive serostatus was associated with
increased odds of having MS only in HLA-DRB1 negative
subjects. (Table 4).
Subanalysis of participants with available
genetic ancestry data
Genetic ancestry inferences were available for 263 cases
and 296 controls. (Tables S1 and S2).
In multivariable logistic regression models adjusted for
sex, age, genetic ancestry, ethnicity and socio-economic
status, seropositivity for EBV-VCA increased the odds of
having MS by more than eight times (OR: 8.26, 95% CI:
4.69–14.53, P <0.001). Although there was no statistically
significant association between HSV-1, HSV-2 and CMV
serostatus and the risk of pediatric MS in this subset of
participants (OR: 1.30, 95% CI: 0.85–2.01, P = 0.23; OR:
1.37, 95% CI: 0.83–2.24, P = 0.22; OR: 1.32, 95% CI:
0.86–1.97, P = 0.17, respectively), the effect sizes were
similar to the main analyses and the lack of statistical sig-
nificance is likely due to the smaller sample size.
Discussion
Environmental exposures explain a large proportion of
MS risk.19 In this large, multicenter, multi-racial and
multi-ethnic case–control study, we demonstrated that
race, genetic background and age change the effects of
prior infections with common herpesviruses on the risk
of pediatric MS.
Prior EBV infection is thus far the strongest and most
consistent environmental factor associated with pediatric
and adult-onset MS.9–13,20,21 We observed that this associ-
ation with pediatric MS is seen regardless of race and eth-
nicity, although the association is stronger in whites, as
recently reported in adult-onset MS.14 Differences in the
magnitude of the association of EBV infection with the
risk of MS among different races and ethnicities point to
potential environment-environment or gene-environment
interactions.
We report several additional meaningful interactions
that modify the association between EBV and pediatric
MS. First, in line with previous reports, we observed that
prior EBV infection is a stronger risk factor in carriers of
HLA-DRB1*15:01.7,22 Although, this synergistic effect sug-
gests possible causality of EBV infection in MS develop-
ment, there is also a possibility that carrying HLA-
DRB1*15:01 affects both the risk of MS and susceptibility
to EBV infection. Second, EBV seropositivity is a much
stronger risk factor in older versus younger children
which raises the possibility of a different pathophysiology
in this age group.
Whether HSV affects MS risk remains controversial.23–
25 In this study, HSV infection was modestly associated
with MS risk according, especially in whites raising the
possibility that the disparity between previous reports
might be related to the racial make-up of study popula-
tions. We also confirm an interaction between HLA-
DRB1 status and HSV infection and the risk of MS.4
Although DRB1 is more frequent in whites, a remote
HSV infection was associated with increased MS risk only
in HLA-DRB1*15:01 negative subjects, which is the
reverse interaction we identified for prior EBV infection.
Although the underlying reasons for these differences
remain to be clarified, these results highlight the complex-
ity of gene-environment interactions as infections with
viruses from the same family may have opposing effects
on MS risk in individuals with the same genotype.
Table 4. Stratified analysis based on variables in which the P-value of
the interaction with the serostatus was <0.15.
Effect Odds ratio 95% CI P-value
Race = White
HSV-1: positive vs. negative 2.18 1.35–3.52 0.001
HSV-2: positive vs. negative 2.30 1.32–3.99 0.003
VCA: positive vs. negative 10.64 5.77–19.62 <0.001
Race = Black
HSV-1: positive vs. negative 1.43 0.63–3.26 0.395
HSV-2: positive vs. negative 1.43 0.57–3.59 0.453
VCA: positive vs. negative 6.75 1.43–31.91 0.016
Race = Other
HSV-1: positive vs. negative 0.36 0.11–1.20 0.096
HSV-2: positive vs. negative 0.23 0.04–1.26 0.089
VCA: positive vs. negative 1.96 0.52–7.37 0.319
Stratified analysis based on age
Age < 15
VCA: positive vs. negative 3.29 1.86–5.84 <0.001
Age ≥ 15
VCA: positive vs. negative **
Stratified analysis based on DRB1 status
DRB1*15:01 or 15:03 = positive
HSV-1: positive vs. negative 0.93 0.47–1.84 0.828
DRB1*15:01 or 15:03 = negative
HSV-1: positive vs. negative 1.89 1.17–3.03 0.009
**173 of 174 cases in the older age group were positive for EBV-VCA
antibody, compared to 127 of 200 for controls. Since there was only
one negative case, the model was not stable in this age group.
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We did not find any association between CMV and odds
of pediatric MS. This is in line with a prior report in adults26
but in contrast with two others in children.4,27 Two small
groups of controls were used in our former study which
could explain differences in the findings.4 One control group
included subjects with inflammatory neurological diseases
while the other was recruited during a different time period
and from different sites compared with cases. In contrast,
this study was a larger, multicenter study in which cases and
controls were selected from the same populations and dur-
ing the same time frame, and as such is more likely valid. In
a recent case–control study in adult MS,14 CMV seropositiv-
ity was negatively associated with MS risk only in Hispanics,
but not in Blacks or whites. This observation was interpreted
as a support for the hygiene hypothesis, in which lack of
exposure to common pathogens in childhood increases the
risk of autoimmune disease later in life.
When using genetic ancestry data rather than self-
reported race, the associations between viral serostatus
and risk of pediatric MS remained unchanged except for
HSV possibly because the genetic ancestry data were
available for only a subset of participants, resulting in a
34% decreased sample size.
The strengths of our study include the large number of
cases and controls with diverse racial and ethnic back-
grounds recruited at several US centers, the relatively short
disease duration of cases (mean < 1 year) and the adjusted
analyses for several potential confounders. The study also
has several limitations. Serological testing was done after dis-
ease onset and our sample is not population-based, that is,
unknown selection bias may have influenced the results.
Similar to all observational studies, unmeasured or unknown
confounders might have affected the results. As mentioned
previously, we did not analyze EBNA-1 seropositivity
because the manufacturing source of the antigen changed
during the study and the results were not consistent. While
antibody responses against VCA are universally present in
EBV exposed persons, EBNA-1 IgG is not produced in about
5% of patients after EBV infection and in some individuals,
it may disappear over time.28 Hence, the anti-VCA IgG is a
more reliable indicator of previous EBV exposure.
Although this study does not explain how environmen-
tal factors affect MS risk in children at the molecular
level, it highlights the complexity of factors at play. Larger
case–control studies will allow further modeling of the
interactions between viral infections, and other environ-
mental and genetic factors.
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